Skip to main content
. Author manuscript; available in PMC: 2010 Sep 1.
Published in final edited form as: Toxicol Appl Pharmacol. 2008 Nov 27;239(2):130–136. doi: 10.1016/j.taap.2008.11.011

Figure 4. MMAIII treatment activates transcription of TrxR1 promoter through the ARE element.

Figure 4

WI-38 cells were transiently transfected with TrxR1 and mutant TrxR1 (mutation in ARE) promoter fusion constructs that have been previously described (Hintze et al., 2003b). Cells were treated with MMAIII at the concentrations indicated in triplicate for each construct for 24 hours prior to assaying Firefly and Renilla luciferase activity. Fold luciferase activity is plotted and based on the ratio of Firefly luciferase to Renilla luciferase activity. The error bars represent standard deviation and student’s t-test was used for statistical analysis. In WI-38 cells transfected with the TrxR1 construct and exposed to 2 μM MMAIII there is a significant increase (*, p < 0.05) in luciferase activity. This increase in luciferase activity is not observed with the mutant ARE construct.